Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
$0.89
-0.5%
$1.01
$0.66
$17.75
$5.45M0.22795,862 shs33,900 shs
BioVie Inc. stock logo
BIVI
BioVie
$0.96
-0.9%
$1.05
$0.62
$7.50
$18.02M0.731.85 million shs122,627 shs
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$1.12
+6.7%
$1.18
$7.80
$12.38
$19.32MN/A41,322 shs435,824 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.44
$1.66
$1.38
$53.79
$17.57M-0.07200,113 shs52,824 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
-0.55%+3.00%-14.13%+2.88%-44.53%
BioVie Inc. stock logo
BIVI
BioVie
-0.87%-6.60%-13.33%+24.13%+131.36%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
+6.67%-5.08%+10.89%+3.23%-67.35%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
0.00%-7.10%-25.00%-12.20%-91.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.6002 of 5 stars
0.05.00.00.00.60.00.6
BioVie Inc. stock logo
BIVI
BioVie
0.8907 of 5 stars
0.04.00.00.02.70.00.6
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.2332 of 5 stars
3.14.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.00
N/AN/AN/A
BioVie Inc. stock logo
BIVI
BioVie
4.00
Strong BuyN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00
N/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.25
Hold$12.17744.91% Upside

Current Analyst Ratings Breakdown

Latest ATNF, JATT, BIVI, and QTTB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
6/11/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/24/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/10/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
4/24/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
4/8/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/AN/AN/AN/A$2.91 per shareN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$2.54 per shareN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/A$0.04 per share27.08($0.53) per shareN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.16M15.14N/AN/A$0.47 per share3.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
-$6.17MN/A0.00N/AN/A-147.32%-76.99%8/11/2025 (Estimated)
BioVie Inc. stock logo
BIVI
BioVie
-$32.12M-$7.91N/AN/AN/A-100.88%-78.49%8/21/2025 (Estimated)
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$6.85MN/A0.00N/AN/A-49.58%2.84%N/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$47.73M-$4.94N/AN/AN/AN/A-447.33%-59.77%8/6/2025 (Estimated)

Latest ATNF, JATT, BIVI, and QTTB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/A-$0.67N/A-$0.67N/AN/A
5/12/2025Q3 2025
BioVie Inc. stock logo
BIVI
BioVie
-$0.32-$0.15+$0.17-$0.15N/AN/A
5/8/2025Q1 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.23-$0.90+$0.33-$0.90N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/AN/AN/AN/AN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/A
1.02
1.02
BioVie Inc. stock logo
BIVI
BioVie
N/A
9.31
9.31
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/A
0.15
0.15
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
1.68
4.71
4.71

Institutional Ownership

CompanyInstitutional Ownership
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
4.07%
BioVie Inc. stock logo
BIVI
BioVie
4.59%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
47.97%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%

Insider Ownership

CompanyInsider Ownership
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.17%
BioVie Inc. stock logo
BIVI
BioVie
2.39%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
20.00%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
40.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
76.07 million6.06 millionNo Data
BioVie Inc. stock logo
BIVI
BioVie
1018.57 million18.13 millionNo Data
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
317.25 million13.80 millionNot Optionable
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3912.20 million7.32 millionN/A

Recent News About These Companies

Q32 Bio (NASDAQ:QTTB) Stock Rating Upgraded by Wall Street Zen
Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)
Q32 Bio price target lowered to $15 from $16 at Wells Fargo
Q32 Bio: Q4 Earnings Snapshot
Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart
Piper Sandler Downgrades Q32 Bio (QTTB)
BMO Capital Downgrades Q32 Bio (QTTB)

New MarketBeat Followers Over Time

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNF

$0.89 0.00 (-0.55%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$0.89 +0.00 (+0.11%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

BioVie stock logo

BioVie NASDAQ:BIVI

$0.96 -0.01 (-0.87%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$0.98 +0.01 (+1.35%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

JATT Acquisition stock logo

JATT Acquisition NYSE:JATT

$1.12 +0.07 (+6.67%)
As of 07/2/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$1.44 0.00 (0.00%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$1.44 0.00 (0.00%)
As of 07/3/2025 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.